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Renin–angiotensin systemKinins are generated within inﬂammatory tissue microenvironments, where they exert diverse functions,
including cell proliferation, leukocyte activation, cell migration, endothelial cell activation and nocicep-
tion. These pleiotropic functions depend on signaling through two cross talking receptors, the constitu-
tively expressed kinin receptor 2 (B2R) and the inducible kinin receptor 1 (B1R). We have reviewed
evidence, which supports the concept that kinin receptors, especially kinin receptor 1, are promising tar-
gets for cancer therapy, since (1) many tumor cells express aberrantly high levels of these receptors; (2)
some cancers produce kinins and use them as autocrine factors to stimulate their growth; (3) activation
of kinin receptors leads to activation of macrophages, dendritic cells and other cells from the tumor
microenvironment; (4) kinins have pro-angiogenic properties; (5) kinin receptors have been implicated
in cancer migration, invasion and metastasis; and (6) selective antagonists for either B1R or B2R have
shown anti-proliferative, anti-inﬂammatory, anti-angiogenic and anti-migratory properties. The multiple
cross talks between kinin receptors and renin–angiotensin system (RAS) as well as its implications for
targeting KKS or RAS for the treatment of malignancies are also discussed. It is expected that B1R antag-
onists would interfere less with housekeeping functions and therefore would be attractive compounds to
treat selected types of cancer. Reliable clinical studies are needed to establish the translatability of these
data to human settings and the usefulness of kinin receptor antagonists.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. The kallikrein–kinin system
1.1. Kinins
Bradykinin (BK), an active peptide produced by the kallikrein–
kinin system (KKS), was ﬁrst reported by the Brazilian pharmacolo-
gist Mauricio Rocha e Silva and his coworkers in 1949. BK was
released when human plasma was mixed with venom of the snake
Bothrops jararaca or with trypsin. On isolated guinea pig ileum, the
substance produced slow delayed contractions when compared to
those obtained with histamine and acetylcholine. The name bradyki-
nin was then given to express this slow action (brady meaning slow
and kinin indicating movement in Greek) [140].
The KKS is complex, with several bioactive peptides that are
formed in many different compartments. Kinin peptides areimplicated in many pathophysiological processes including the
regulation of blood pressure and sodium homeostasis, inﬂamma-
tory processes, renal, cardiac and neurological functions, pain
sensation, smooth muscle contraction, and cell proliferation and
migration [37].
The KKS represents a metabolic cascade, which upon activation
triggers the release of vasoactive kinins (Fig. 1). In humans and in
most mammals, the term ‘‘kinin’’ refers to the nonapeptide, BK
(Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg), the decapeptide kallidin
(KD: Lys-BK), the methionyl-lysyl-BK, and their carboxy-terminal
des-Arg metabolites. BK-(1-7) is an inactive degradation product,
whereas BK-(1-5) is involved in the coagulation system. Kinins
are released locally from their parental molecules, the kininogens,
as a result of limited proteolysis by a class of serine proteases
called kallikreins (plasma and tissue kallikreins). Enzymes collec-
tively called kininases metabolize kinins in various site of cleavage;
these include angiotensin-converting enzyme (ACE), neutral
endopeptidase (NEP), carboxypeptidase N, carboxypeptidase M,
cathepsin X and aminopeptidase P (APP) [16]. BK is metabolized
rapidly by endogenous metalloproteases having a plasma half-life
of approximately 15 s and usually low circulating levels. The broad
spectrum of their actions is mediated by G protein-coupled recep-
tors (GPCRs), pharmacologically classiﬁed as kinin receptor sub-
type 1 (B1R) and kinin receptor subtype 2 (B2R) [84].
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Fig. 1. Schematic representation of the kallikrein–kinin system. The kininogens HMWK and LMWK are cleaved by tissue and plasma kallikreins, respectively, generating the
metabolites BK and Lys-BK, respectively, which can be cleaved by the kininases CPN and CPM generating respectively the metabolites des-Arg9-BK and Lys-des-Arg9-BK. Lys-
BK and BK are agonists of B2R and Lys-des-Arg9-BK and des-Arg9-BK are agonists of B1R.
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Kinins exert their pharmacological activities by binding speciﬁc
receptors: B1R and B2R. BK and KD preferentially bind to B2R,
whereas the carboxy-terminally truncated peptides desArg9-BK
and desArg10-KD have a high afﬁnity to B1R. Depending upon the
cell type, kinins induce excitability, cell division, permeability,
and release of a variety of biologically active agents [17]. Due to
the multiple roles of kinins, many signaling pathways have been
shown to be activated, notably the mitogen-activated protein ki-
nase (MAPK), PKC and nuclear factor-jB (NF-jB) pathways
[66,121].
Kinin receptors are coupled to G proteins leading to the activa-
tion of a number of signaling molecules, such as, several isoforms
of protein kinase C (PKC) and phospholipases and the generation
of second messengers, such as inositol-1,4,5-trisphosphate, diacyl-
glycerol, calcium and arachidonic acid (subsequently converted to
prostaglandins). The increase in calcium can also activate the
endothelial nitric oxide (NO) synthase (eNOS) and ultimately the
production of NO in endothelial vasculature [25,41,148]. Novel sig-
naling molecules continue to be identiﬁed in the diverse ﬁelds
where kinins have a role, such as the Rho-kinases (ROCKs) in the
bradykinin-induced increase in murine blood–tumor barrier per-
meability and the myristoylated alanine-rich C kinase substrate
(MARCKS) in bradykinin-induced neurite outgrowth in neuroblas-
toma cells [90,162]. The remarkable diversity of pathways used by
kinin receptors may reﬂect cell-type speciﬁc responses elicited by
them.
B1R and B2R activation triggers essentially the same signaling
pathways. However, the patterns of signaling are different in terms
of cell Ca2+ inﬂux (in duration and in intensity) [107]. Kinin-stim-
ulated B2R signaling is often transient, whereas B1R signaling is
sustained. Enquist et al. proposed recently that this may be, at least
in part, because kinin-stimulated B1R signaling depends on a step
in receptor endocytosis, whereas B2R signaling does not [55]. Some
studies have reported cross talk between B1R and B2R with evi-
dence that persistent stimulation of B2R may result in up-regula-
tion of B1R [127]. Recently, Rodrigues et al. have provided some
evidence that B2R expression is highly upregulated by endothelial
overexpression of B1R studying thoracic aorta from transgenic rat
overexpressing B1R exclusively in the vascular endothelium [141].Some indirect mechanisms of kinin receptor activation have
been proposed, where the formation of protein complexes on the
membrane surface may be a key event. Binding of carboxypepti-
dase M (CPM) to B1R allosterically enhances B1R afﬁnity for its
des-Arg kinin agonist. In addition, kinin substrate (i.e., BK or KD)
binding to the CPM active site causes a conformational change in
CPM that is transmitted via protein–protein interaction to the
B1R, resulting in G protein coupling and activation of calcium, ni-
tric oxide (NO) or ERK signaling [192–194]. Similarly, experimental
evidence suggests that the binding of some ACE inhibitors cause a
conformational change in ACE that potentiates B2R signaling [56].
Typically, B2Rs are constitutively expressed whereas B1R
expression is up-regulated under conditions such as tissue injury,
cytokine stimulation and inﬂammatory insults [136,138], events
highly relevant to cancer. However, some tissues such as the spinal
cord and some brain regions and cells express B1Rs constitutively
[89,129,183]. In addition, B2R expression can be modulated by
inﬂammatory cytokines, such as interleukin (IL)-1, Tumor Necrosis
Factor (TNF)-a and Transforming Growth Factor (TGF)-b
[11,22,78]. Both receptor subtypes for kinins can be expressed by
the same cell type, such as, endothelial cells, ﬁbroblasts and vari-
ous tumor cells [184].
2. Kinin receptor antagonists
The development of potent and selective kinin receptor modu-
lators has led to the production of a number of peptide and non-
peptide agonists and antagonists. However, only one compound,
Icatibant (HOE-140) – a hydrophilic decapeptide selective for the
B2R – has reached the market for the treatment of hereditary
angioedema.
The ﬁrst family of compounds capable of antagonizing BK and
des-Arg9-BK with speciﬁcity was based on the prototype [Leu8]-
des-Arg9-BK [135]. The ﬁrst generation of B2R antagonists were
based on [D-Phe7]-BK [172], but these early peptide compounds
showed both antagonist and partial agonist activity and low po-
tency. Second generation peptide antagonists of kinin receptors
are quite selective and present relatively long-lasting in vivo ac-
tion: these include the highly selective B1R antagonist R-954 and
the B2R antagonist HOE-140 [85,114]. Third generation antago-
nists of kinin receptors, are orally active, and include SSR240612
P.L.N. da Costa et al. / Cancer Letters 345 (2014) 27–38 29and MEN16132 (fasitibant) [63,64,158]. For a more comprehensive
review see Whalley et al. [182] and Bozo et al. [21].
A certain number of clinical trials have been performed with
peptide and non-peptide B1R and B2R ligands (Table 1). however,
only two of these developments disregards cancer treatment: the
B2R agonist RMP-7 (lobradimil) and the dual B1R and B2R antago-
nist B9870 (breceptin). In pre-clinical studies of rats with im-
planted gliomas, intravenous lobradimil signiﬁcantly increased
the uptake of carboplatin into brain tumors [53]. A phase II trial
of lobradimil and carboplatin was conducted in pediatric patients
with glioma. Unfortunately, the combination of lobradimil and car-
boplatin was inactive in childhood gliomas [131,179]. Apoplogic
Pharmaceuticals has conducted a phase I trial with B9870 in lung
cancer, however we were unable to ﬁnd further information about
this development.
The analysis of Table 1 discloses a disappointing scenario. Most
clinical studies with kinin antagonists have been halted for undis-
closed reasons. It is likely that multiple factors, such as limitations
in the predictive power of animal models, poor absorption/distri-
bution/metabolism/excretion proﬁle of some of the compounds,
or toxicological problems might be attributable for halting these
developments [21,182]. There is a need for improved animal
models, particularly with increased use of humanized systems
and non-human primates, to improve the translatability from
animal models to human disease [61,72].3. Implications of kinin receptor activation in cancer
A role for kinin receptors in cancer has been suggested in a
number of studies [36,60,159,191]. The ability of kinins to stimu-
late cell proliferation, migration and angiogenesis, and increase
vascular permeability, probably contributes to the biological
behavior of tumors (Fig. 2). In addition, kinin receptors could play
an important role in cancer growth and metastasis, since these are
critically dependent on the activation of inﬂammatory pathways.
Moreover, kinin receptors have been implicated in cancer painTable 1
Selected clinical trials with B1R and B2R agonists and antagonists.
Drug Target Clinical phase Indication
HOE-140
(Icatibant, Firazyr)
B2R antagonist Approved Hereditary angioedema
Phase I/II/III Ischaemic heart diseases, car
bypass, inﬂammation, ﬁbrino
ACE inhibitor-associated ang
MEN16132 (fasitibant) B2R antagonist Phase II Knee pain in osteoarthritis
CP-0127 (deltibant) B2R antagonist Phase II Severe traumatic brain injury
LF16-0687 (anatibant) B2R antagonist Phase II Severe traumatic brain injury
RMP-7 (lobradimil) B2R agonist Phase II Intravenous cereport (RMP-7
carboplatin in childhood brai
FOV-2304 (safotibant) B1R antagonist Phase II Diabetic macular edema
MK-0686 B1R antagonist Phase II Postherpetic neuralgia
Postoperative dental pain
Osteoarthritis
BI-113823 B1R antagonist Phase I Osteoarthritis
SSR-240612 B1R antagonist Reported
Phase II
B9870 Phase I Small cell lung cancer
(Breceptin)
B1R, kinin receptor 1; B2R, kinin receptor 2; ACE, Angiotensin-converting enzyme; NCTand kinin receptor antagonists appear to alleviate nociception
associated with chemotherapy-induced peripheral neuropathy, a
condition that limits treatment of cancer patients [23,62,150].3.1. Kinin receptor expression in cancers
Several studies reported that the expression of B1R in cancers
including renal, esophageal, cervical, gastric, prostate, lung and
mammary carcinomas and malignant mesothelioma, as well as
cancer cell lines (Table 2) [10,32,33,46,57,62,102,104,116,
133,146,175,184]. B2R has also been detected in different cancers,
including head and neck squamous cell carcinoma (HNSCC), osteo-
sarcoma, endometrial, prostate, renal, cervical, lung and stomach
cancers, lymphoma, hepatoma, mesothelioma and pituitary ade-
noma (Table 2) [13,33,35,104,111,137,167,176,184,191]. Studies of
receptor expression levels have suggested a role for B1R and/or
B2R in malignant transformation and tumor progression (Table 2).
However, only six studies evaluated the expressionof kinin receptors
in sample sizes of more than 30 patients. In addition, four of them
only evaluated one out of the two receptors. There is a need to ex-
pand the knowledge about the expression of these receptors in tu-
mor progression of various cancers, particularly lung and prostate
cancer and melanoma.
Previous studies revealed an increased number of B2Rs in cells
transformed by the activation of oncogenes. The increase in recep-
tor number is a ras speciﬁc event (rather than a general effect of
transformation) and occurs after overexpression of each of the
three normal ras gene products (Ha-, K- and N-) as well as after
expression of the three activated ras gene products [48,126]. In
addition, the dbl (human diffuse B-cell lymphoma) oncogene is also
shown to increase the expression of bradykinin receptors in NIH
3T3 cells to the same extent as ras whereas other oncogenes
(v-src, v-abl, v-mos, v-raf, v-fos) did not have this effect [142].
Expression of a mutant ras protein in Rat 13 cells increases the
expression of the B2R and their sensitivity to ligand stimulationComments Ref.
Approved for angioedema and in trial for
many other conditions
[8,30]
diopulmonary
lysis, surgery,
ioedema etc.
Decreased intraoperative ﬁbrinolytic
capacity in cardiopulmonary bypass
A ﬁrst phase II study (ALBATROSS) has
been completed. A second one is ongoing
[63] NCT0109116
sepsis Phase 2 trial was halted due to
unexpected preclinical ﬁndings.
Ineffective for sepsis
[58,96,112]
Inconclusive results, possible safety
concerns
[152]
) and
n tumors
Fail to show improved efﬁcacy [131,179]
No results released. It was discontinued in
October 2012
NCT01319487
The development was halted. No speciﬁc
reason was disclosed
NCT00292763
NCT00533403
NCT00296569
Phase 1 clinical study was terminated
due to unknown reasons
NCT01207973
The development was halted for an
undisclosed reason
No record found
No information found
, National Clinical Trial (http://www.clinicaltrials.gov).
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Fig. 2. Schematic drawing of some mechanisms involved on the activation of kinin
receptors within tumor microenvironment. It has been suggested, according with
in vitro and in vivo studies, that kinin receptors activation in different cells that
compose the tumor microenvironment results in a range of actions, such as the
release of MMPs, growth factors and inﬂammatory mediators, which can promote
tumor growth, angiogenesis, invasion and cancer metastases.
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regulates BK expression/actions are still unknown.3.2. Kinins as growth factor for cancer cells
Some cancers produce BK and use it as an autocrine factor to
stimulate their growth, notably small cell lung carcinoma (SCLC),
prostate and breast cancer and certain ascites tumors [9,24,160].
Using prostate cancer PC3 cells as a model for the study of andro-
gen-insensitive prostate cancer, Taub and others showed that spe-
ciﬁc inhibition of B1R signaling attenuates in vitro cell growth,
migration, and invasion. The activation of B2R also induced prolif-
eration of PC3 cells [9,163] and other cancer cell lines [49,65,81].
BK-induced PC3 cell growth requires activation of the ERK pathway
[10]. In normal and cancerous breast cells, BK stimulated cell pro-
liferation through the activation of MAPK pathways [49,65,66,164].
The proliferative effect of BK was higher in tumor cells with respect
to nonmalignant epithelium adjacent to the tumor. Greco et al.
suggested that BK leads to cell proliferation through B2R activation
[67]. Molina and colleagues have shown that stimulation of B1R in-
duced the proliferation of estrogen-sensitive breast cancer cells
and ERK1/2 phosphorylation is essential for proliferation [102].
Antagonists for either B1R or B2R have been proposed for the
treatment of various cancers, particularly lung, prostate and breast
cancers [84,108]. The compound B-9870 (also known as CU-201)
inhibits tumor cell growth both in vitro and in vivo in athymic nude
mice [159]. B-9870 was shown to induce apoptosis in various lung,
prostate and HNSCC cell lines [28,29,159,164]. B-9870 stimulated
apoptosis in lung cancer cells by a novel ‘‘biased agonist’’ mecha-
nism: it inhibited intracellular Ca2+ released in response to BK,
which indicated blockage of the Gaq signal, and stimulated c-Jun
kinases, which suggested stimulation of the Ga12,13 pathway. This
unbalanced action ultimately stimulated caspase-3 activity and led
to cell death [28,29,73]. B-9870 also produced increased growth
inhibition when combined in vitro with chemotherapeutic agents
used routinely to treat lung cancer patients [paclitaxel, doxorubi-
cin (DOX), etoposide, and vinorelbine] [29]. However, Morissette
and colleagues found that B-9870 is a dual B1R and B2R antagonist
with conﬁrmed stimulating effects at the B2R in cells and tissues
where B2Rs are overexpressed [108]. Importantly, inhibition of
MDA-MB-231 cell growth by B-9870 was not inﬂuenced by B1R
or B2R antagonists [108]. Thus, the mechanism of action ofB-9870 may not be necessarily related to BK antagonist activity.
These results should be interpreted with caution.
3.3. Kinins as novel cancer biomarkers
Despite the need to identify clinically useful biomarkers for
detection of early disease, there have been only a few examples
of circulating molecules that can be used to detect cancers before
they are clinically evident. Maeda et al. have identiﬁed a new type
of BK, 3-hydroxyprolyl (3Hyp)-BK, in ascitic ﬂuid of gastric cancer
patient [92]. Subsequently, high amounts of both 3Hyp-BK and
BK, and both BK/Hyp–BK were found in ascitic and pleural ﬂuids
of human and animal carcinomatosis [97,98].
Recently, Villanueva et al. found that BK and des-Arg9-BK levels
are at higher levels in sera of breast cancer patients and lower in
bladder cancer patients when compared with normal subjects,
using optimized mass spectrometry [173]. Subsequent studies con-
ﬁrmed that des-Arg9-BK, was present at increased levels in breast
cancer patients and the concentration of this peptide decreased
to normal levels after removal of the tumor [170]. Further studies
are needed to conﬁrm the potential of BK and, especially, des-Arg9-
BK as biomarkers for the diagnosis and therapeutic management of
cancer patients.
3.4. Kinins as pro-inﬂammatory molecules
There is compelling evidence indicating that kinins are gener-
ated rapidly after tissue injury and they seem to modulate most
events observed during inﬂammatory processes including vasodi-
latation, increase of vascular permeability, plasma extravasation,
cell migration, pain, and also synthesis of inﬂammatory mediators
such as eicosanoids, cytokines and nitric oxide (NO) [26]. Several
lines of evidence indicate that kinins play a critical role in different
inﬂammatory pathological states such as infections, ischemia–
reperfusion injury and cancer [36,94,163,177,178].
One of the ﬁrst correlations between kinins and inﬂammation
came from the observation that the administration of BK in human
or animal tissues reproduced the four cardinal signs of inﬂamma-
tion: redness, local heat, swelling, and pain [53]. Many subsequent
studies have established that both B1R and B2R are involved in the
onset and maintenance of inﬂammation [27,39,135].
B1R expression is induced by several different pro-inﬂamma-
tory cytokines including IL-1b, TNF-a, interferon-c, EGF, IL-2 and
IL-8 [20,42,43,68,101,130,147]. These cytokines activate distinct
cytokine receptors and often regulate different pathways, mainly
via NFjB signaling, which in turn activates the expression of the
very same cytokines and B1R in an ampliﬁcation cascade
[26,115]. Thus, there is a complex interaction between the B1R
and pro-inﬂammatory cytokines that may play an important role
in tumor progression and metastasis.
Recently, it was shown that the B1R antagonist R-954 inhibited
Ehrlich ascitic tumor (EAT) growth in mice and reduced paw ede-
ma after intraplantar injection of EAT cells in rats, resulting in in-
creased survival of animals. In addition, R-954 reduced
signiﬁcantly the extravasation of protein, the production of NO
and PGE2, and release of TNF-a in the mouse peritoneal cavity [59].
Kinins play an important role in the activation of various leuko-
cytes during the inﬂammatory process, especially by the release of
other inﬂammatory mediators, such as cytokines, prostaglandins,
leukotrienes, and reactive oxygen species. B2R on neutrophils is in-
volved in the extravascular migration of these cells at sites of
inﬂammation [119,129,144,145]. Ablation of the B1R gene in mice
is associated with a defect in neutrophil accumulation in inﬂamed
tissues [5,129]. Furthermore, activation of B1R in human neutro-
phils induces chemotaxis and triggers the release ofmatrixmetallo-
proteinases (MMP)-9 and myeloperoxidase [51,52]. Macrophages
Table 2
B1R and B2R expression in clinical samples from cancer patients and cancer cell lines.
Study Clinical
specimens
Ref.
Increased levels of B1R was found in colorectal adenomas, which tend to evolve into colonic cancer, and increased levels of B2R was found in
hyperplastic polyps (no neoplastic potential)
B1R, n = 41 [189]
B2R, n = 41
B1R and B2R were detected in human astrocytic tumors B1R, n = 10 [133]
B2R, n = 12
B1R and B2R were detected in human gastric carcinoma specimens B1R, n = 17 [146]
B2R, n = 11
B1R and B2R were detected in human oesophageal carcinoma, however not highly expressed compared with normal counterpart B1R, n = 10 [46]
B2R, n = 6
B1R and B2R were detected in human clear-cell renal carcinoma tissue and adjacent tissue B1R, n = 4 [104]
B2R, n = 4
Both B1R and B2R are expressed in human pleural mesothelioma B1R, n = 4 [33]
B2R, n = 4
B1R and B2R were detected in ﬁve different subtypes of human lung cancer B1R, n = 4–6 [31]
B2R, n = 3–6
B1R expression was increased in human bladder cancer samples, while B2R was not. B1R and B2R agonists stimulated the proliferation of
grade 3-derived T24 bladder cancer cells and antagonists for both receptors inhibited this proliferation (in vitro)
B1R, n = 7 [151]
B2R, n = 7
B1R mRNA levels were found higher in patients with grade 2 endometrial cancer when compared to the control group and both B1R and B2R
presented lower levels in patients with grade 3 endometrial cancer, compared with control, grades 1 and 2
B1R, n = 50 [117]
B2R, n = 50
B1R and B2R mRNA were detected in human chondrosarcoma tissues at higher expression compared to normal cartilage B1R, n = 3 [185]
JJ012 chondrosarcoma cells express both B1R and B2R. Antagonism of any kinin receptor attenuated kinin-induced cell migration (in vitro) B2R, n = 3
B2R was found ubiquitously expressed in prostate tissues. B1R was detected only in prostatic intraepithelial neoplasia and malignant
lesions and not in benign prostate tissues. Stimulation of B1R on PC3 cells promotes cell growth, migration, and invasion (in vitro)
B1R, n = 16 [163]
B2R, n = 16
Prostate cancer PC3 cells express B1R and B2R. Speciﬁc blockade of either B1R or B2R is sufﬁcient to cause inhibition of kinin-mediated cell
proliferation. Blockade of B1R also inhibited B2R-mediated cell growth, and, similarly, antagonism of B2R inhibited the B1R-mediated
response
[9]
B1R was detected in precursor lesions of gallbladder carcinoma, but showed a low expression in invasive carcinomas. HER-2 receptor was
highly expressed in intestinal metaplasia and carcinoma in situ, but not in invasive carcinoma (similar to B1R)
B1R, n = 92 [166]
B2R was detected in clinical specimens of gastric adenocarcinoma, squamous cell lung carcinoma, duodenal carcinoid, lung papillary
adenocarcinoma, hepatoma and Ki-1 lymphoma. B1R expression was not determined
B2R, n = 1 [184]
B1R transcripts were detected in invasive breast carcinomas (79/216). In patients with estrogen receptor-negative tumors (n = 42), B1R
mRNA expression correlated with longer disease-free survival. B2R expression was not determined
B1R, n = 216 [57]
B1R was found in benign and malignant neoplastic human breast tissues. B1R and B2R agonists induce proliferation of MCF-7 breast cancer
cells. B1R antagonist inhibited kinin-induced MCF-7 proliferation, but no B2R antagonists were tested
B1R, n = 21 [102]
BK induced the phosphorylation of ERK1/2 in MCF-7, which was inhibited by a B2R antagonist, but not by a B1R antagonist. BK also
stimulated the proliferation of MCF-7
[67]
B2R antagonist reduced angiogenesis and tumor weights in rats bearing Walker 256 carcinoma. A B1R antagonist did not change tumor
growth. B2R protein was mainly detected in the tumor stromal tissues. B1R was not detected. Angiogenesis and tumor growth were
signiﬁcantly suppressed in B2R knockout mice bearing sarcoma 180
[74]
The growth and angiogenesis of murine sarcoma 180 cells was reduced by a B2R antagonist but not by a B1R antagonist. B2R protein was
mainly expressed in vascular endothelial cells in the early phase and in ﬁbroblast-like cells of the stroma in the late phase
[75,76]
A B1R antagonist inhibited Ehrlich ascitic tumor growth in vivo. The expression of kinin receptors has not been determined [59]
Over-expression of B2R was determined in HNSCC human tissues in comparison to normal peritumoral tissue. B1R expression was not
determined
B2R, n = 180 [13]
In HNSCC samples, B2R levels were 3-fold higher in tumor tissue compared with normal control tissue. B1R was detected in only a small
percentage of tumors. The B2R antagonist, but not the B1R antagonist, inhibited bradykinin-induced EGFR and MAPK activation and COX-
2 induction in HNSCC cell lines
B2R, n = 43 [191]
The expression of B2R in the three grades of glioma was in the order of aggressiveness (WHO I < WHO II < WHO III) B2R, n = 24 [195]
BK, acting via B2R, acts as an important signal directing the invasion of glioma cells toward blood vessels. Most experiments were performed
on D54-MG glioma cells, which express high levels of B2R and low levels of B1R
[103]
BK-induced cell migration and COX-2 production were inhibited by a B1R antagonist (in vitro) in C6 and U251 glioma cells, which express
both B1R and B2R
[88]
COX, cyclooxygenase; EGFR, epidermal growth factor receptor; ERK, extracellular-signal-regulated kinase; HER, human epidermal growth factor receptor; HNSCC, head and
neck squamous cell carcinoma; WHO, World Health Organization.
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eration of various inﬂammatory mediators, such as TNF, IL-1 and
PGE2 [18,143,165]. T lymphocytes appear to express only the B1R,
the activation of which could alter their migration in selected tis-
sues during inﬂammation, including in central nervous system
[99,118,149]. Immature human monocyte-derived dendritic cells
constitutively express B1R and B2R, and BK increased the in vitro
migration of these cells [14]. All these results suggest that kinin
receptorsmight play a pivotal role in the recruitment of pro-inﬂam-
matory cells within the tumor microenvironment.
Our group has provided some insights into the relevance of B1R
in leukocyte inﬁltration within tumors and its consequences in
tumor engraftment and growth in response to apoptotic cells.Previously, we have shown that the co-injection of dying cells
along with sub-tumorigenic doses of melanoma cells favored mel-
anoma growth. The presence of apoptotic cells causes a transient
inﬂammatory inﬁltrate, composed mainly of neutrophils and mac-
rophages. This effect was suppressed in B1R–deﬁcient mice, which
have impaired transmigration of neutrophils to inﬂamed tissues
[36]. On the basis of these results, we suggest that disrupting the
balance between apoptotic cells and leukocyte inﬁltration may
provide insights for understanding and interfering with tumor cell
viability during treatment with apoptosis-inducing drugs. Accord-
ingly, we observed increased inﬁltration of B1R-positive cells with-
in the tumor microenvironment of dacarbazine-treated
melanoma-bearing mice.
Fig. 3. The gradient of doxorubicin ﬂuorescence intensity in relation to distance
from the nearest blood vessel. Mice bearing EMT6 tumors (n = 6 tumors) were
treated with saline (control) and the B1R antagonists R-715 (0.5 mg/kg) or R-954
(3 mg/kg s.c.) followed by doxorubicin intravenous injection 2 h later and their
tumors were resected, sectioned and imaged. Image analysis was undertaken using
customized algorithms. The graph shows the mean absolute (background-sub-
tracted) values of ﬂuorescence intensity of doxorubicin for the three different
treatments, as a function of distance to the nearest tumor vessel. *p < 0.001.
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The relevance of angiogenesis for tumor growth and metastasis
has been long recognized. Kinins can promote angiogenesis in dif-
ferent experimental models of normal and cancer cells/tissues,
through B1R, B2R or both.
BK induced angiogenesis in rabbit corneas and on postcapillary
venular endothelial cells through B1R and Fibroblast Growth Fac-
tor (FGF)-2 up-regulation [105,125]. Loiola and colleagues pre-
sented evidence that the targeted deletion of B1R or B2R impairs
endothelium mediated vasodilation by reducing NO bioavailability
in mesenteric arterioles [87]. Indeed, evidences indicate that B2R
and B1R activation in endothelial cells leads to the generation of
NO via activation of different eNOS and iNOS (reviewed by Kuhr
et al. [83]).
Studying mice bearing sarcoma 180 cells, Ishihara and col-
leagues suggested that BK would promote angiogenesis by increas-
ing vascular permeability in the early phase of tumor development
via B2R expressed in the endothelial cells and not via B1R, and by
promoting the up-regulation of Vascular Endothelial Growth Fac-
tor (VEGF) via B2R in the stromal ﬁbroblasts in the late phase
[74–76]. Tumor-associated angiogenesis and tumor growth were
markedly attenuated in B2R knockout mice and in mice treated
with B2R antagonists in two rodent models of mice genetically
deﬁcient in the kallikrein–kinin system and in Walker 256 carci-
noma [74]. Recently, Yu and co-workers found that exogenous
BK increased VEGF expression in prostate cancer cells (PC3 and
DU145 cells) and further promoted tube formation in endothelial
cells. The B2R antagonist HOE140 or small interfering RNA (siRNA)
reduced BK-mediated VEGF production by the cancer cells. In addi-
tion, BK knockdown reduced VEGF expression and abolished pros-
tate cancer cell conditional medium-mediated angiogenesis [187].
Anti-cancer drugs access solid tumors via blood vessels, and
must penetrate tumor tissue to reach all cancer cells. Previous
studies conducted in Dr. Tannock’s laboratory have demonstrated
steep gradients of decreasing doxorubicin ﬂuorescence with
increasing distance from blood vessels, which suggested that many
tumor cells may not be exposed to sufﬁcient concentration of the
drug [128,132]. Our results show that treatment of mice bearing
EMT6 sarcoma with the B1R antagonists R-954 and R-715 resulted
in enhanced doxorubicin penetration after 2 h of treatment (Fig. 3).
These results suggested that B1R antagonists might be used in
combination to increase the delivery of certain chemotherapeutic
agents. Intravenous infusions of the B2R agonist RMP-7 enhanced
the delivery of hydrophilic chemotherapeutic agents (carboplatin
and doxorubicin) into brain tumors, through increases in the per-
meability of the blood–brain tumor barrier [54]. The enhanced
delivery increased the efﬁcacy of chemotherapy, suppressed tumor
growth and increased survival in tumor-bearing rats. However, a
randomized phase 2 trial in patients with glioma receiving carbo-
platin with or without RMP-7 suggests that RMP-7 did not improve
the efﬁcacy of carboplatin. This negative clinical result may be due
to sub-optimal dosing of RMP-7 [131]. More recently, it was dem-
onstrated that dual B1R and B2R activation provides enhanced
blood–brain barrier permeability and carboplatin drug delivery in
the malignant F98 glioma rat model, which also translated into in-
creased survival of glioma-bearing rats [38].
3.6. Implication of kinins in cancer migration, invasion and metastasis
Activated MMPs play critical roles for degradation and remodel-
ing of extracellular matrix at the site of cancerous lesions facilitat-
ing angiogenesis, tumor invasion and metastasis [110,157]. It has
been shown that BK induces eNOS and cyclooxygenase (COX), gen-
erating NO and PGs respectively, via B2R [19,93,120,122]. NO and
PGs are involved in angiogenesis stimulated by VEGF and in tumorvascular permeability [109,124]. Furthermore, NO reacts with
superoxide anion radical ðO2 Þ and forms peroxynitrite (ONOO),
which can activate neutrophil- and ﬁbroblast-derived pro-MMPs
leading to the release of MMPs and therefore they may up-regulate
tumor metastasis and angiogenesis [51,93].
Several studies have shown that activation of kinin receptors re-
sults in the transactivation of EGFR and production of MMPs in
cancer cells. B2R activation stimulated the in vitro invasion of
HNSCC via EGFR [164,191]. In addition, in vitro activation of B1R
in breast cancer cells induced the accumulation of MMP-2 and
MMP-9 in the extracellular medium, through the activation of
the ERK1/2 pathway and EGFR transactivation [50]. BK also induces
MMP-9 expression via reactive oxygen species (ROS) dependent
pathways in brain astrocytes [86].
Cancer cells must be able to migrate in order to metastasize. BK
was found to enhance the migration of chondrosarcoma cells by
increasing a2b1 integrin expression through the B1R and B2R/
PLC/PKCd/NF-jB signal transduction pathway [185]. BK, acting
via B2R, stimulates the migration of glioma and bladder cancer
cells in vitro [7,103]. Furthermore, Vassou et al. reported that opi-
oids increase bladder cancer cell migration through their interac-
tion with B2Rs (in the absence of opioid receptors), although this
interaction is of low afﬁnity [171]. BK also promotes migration of
human prostate cancer cells by increasing adhesion molecule
intercellular adhesion molecule-1 (ICAM-1) expression via B2R
[188].
Using simultaneous intracellular calcium concentration ([Ca2+]i)
measurements and electrophysiological recordings, Cuddapah
et al. have elegantly demonstrated that KCa3.1 channel and ClC-3,
a voltage-gated Cl channel/transporter, are activated as a result
of bradykinin-dependent [Ca2+]i increases. In addition, inhibition
of KCa3.1 or ClC-3 channels decreased bradykinin-induced migra-
tion through murine cerebral parenchyma in situ [40].
The above results suggest that tumor cells may bear a BK auto-
crine/paracrine mechanism which could promote the action of ki-
nins, leading to signal ampliﬁcation for tumor growth involving
enhanced tumor vascular permeability, angiogenesis, inﬂamma-
tion and MMP activation. It is indeed noteworthy that tumors are
not only composed of genetically transformed cells (tumor cells),
but also of host cells such as endothelial cells, leukocytes and ﬁbro-
blasts [69], which express the kinin receptors and probably inter-
act in this network. Ikeda and colleagues suggested that BK
generated from host cells may facilitate tumor-associated angio-
genesis and tumor growth by stimulating stromal B2R signaling
to up-regulate VEGF production mainly in ﬁbroblasts [74].
Fig. 4. Interactions between the KKS and the Renin Angiotensin System (RAS). ACE
represents a central physiological bridge connecting the KKS (left side) and the RAS
(classical RAS on the right side). ACE regulates the levels of endogenous Ang II and
kinins by degrading BK and converting Ang I to Ang II. A crosstalk between ACE, B1R
and/or B2R is also postulated in some systems and increases the complexity of
these interactions. Similarly, cross talks between AT1R and AT2R with B2R have also
been described.
P.L.N. da Costa et al. / Cancer Letters 345 (2014) 27–38 33Surprisingly, it was recently reported that melanoma cells
(Tm5) which express B1R, but not B2R, when pre-treated with
B1R agonist produce less aggressive tumors, characterized by de-
creased proliferation and vascularization in vivo [44]. Besides that,
these tumors exhibited a decrease of inﬂammatory cells inﬁltration
and upregulation of the cytokines IL-6 and IFN-c, which may have
a role in host anti-tumor immune response. These animals also
presented no signs of metastasis and increased animal survival
[44]. The authors suggest that activation of the B1R has a host pro-
tective role during murine melanoma progression. According with
these results, B1R is having an anti-tumor role. The authors point
that the pro-tumor role for the B1R, found in most publications,
is likely due to the cross talking effect with the B2R. To reinforce
this idea, they have elegantly shown that introduction of B2R in
Tm5 cells completely abrogated the B1R-mediated effect of
decreasing cell migration.
Indeed, most studies relating the kinin receptors to cancer were
performed in models were tumor cells express both B1R and B2R
(Table 2). A better understanding of the relative functional roles
of the B1R and B2R, both temporally and spatially, as well as its
cross talk, emerges as an essential part of good preclinical and clin-
ical studies. At the same time, in order to evaluate the relevance of
a cancer model where B2R is absent, more studies with larger clin-
ical sample are urgently needed. Meanwhile, B1R antagonists still
show great potential at least for the treatment of tumors that ex-
press both kinin receptors. It is also likely that the therapeutic win-
dow for the use of these antagonists or agonists will need to be
carefully deﬁned.4. Implication of other components of the KKS in cancer: The
kallikreins
The human tissue kallikrein (KLK) family has fundamental roles
in cancer. Individual members of the KLK family such as prostate
cancer-speciﬁc marker KLK3, which is also termed prostate-spe-
ciﬁc antigen (PSA), have been identiﬁed as cancer biomarkers
[180]. Many studies have reported the overexpression of various
kallikreins such as KLK4, KLK5, KLK7, KLK 10 and KLK14 in pros-
tate, ovarian, breast, colorectal cancer and others, as well as its cor-
relation with patients’ diagnosis, outcome and in predicting
chemotherapy response [4,79,80,123,190]. As an example, KLK1
has been implicated in the growth and invasiveness of many can-
cers [6,45,47]. The mechanisms may involve their intrinsic activity
as proteases promoting the degradation of extracellular matrix
[6,100,168] and the activation of kinin receptors either directly
[15] or through the generation of kinins [91]. Moreover, KLK1 gene
silencing reduced endothelial progenitor cells migratory, invasive,
and pro-angiogenic activities. HK1-induced effects are mediated by
a B2R-dependent mechanism involving iNOS and MMP-2 [156].5. Interactions between the KKS and the Renin Angiotensin
System (RAS): Cancer implications
There are links between the KKS and the RAS, which result from
interactions of their multiple components (Fig. 4). ACE represents a
central physiological bridge connecting the RAS and the KKS. By
degrading BK and converting angiotensin (Ang) I to Ang II, ACE
regulates the circulating and tissue levels of endogenous Ang II
and kinins [154,155]. Indeed, BK is much more readily hydrolyzed
by ACE than Ang I [196]. Several studies have revealed that ACE
inhibitors (ACEi) reduce growth and angiogenesis of experimental
tumors [3,113,174,181,186]. Although the mechanisms of ACEi
effects are complex and relate to their speciﬁc pharmacological
properties (for a review see [70]), it needs to be determined
whether the accumulation of kinins generated by ACEi would bepart of ACEi’s anti-tumor effect or if, in fact, it attenuates its overall
effect. The evidences presented here strongly suggest that kinins
are pro-tumor peptides, supporting the notion that ACEi’s anti-tu-
mor effects may be blunted by the secondary effects of increased
levels of kinins and subsequent activation of B1R and/or B2R.
Therefore, it is likely that combination of ACE inhibition and kinin
antagonists may augment anti-tumor responses. In this regards,
the B2R antagonist Icatibant was suggested to augment the effects
of current cytotoxic chemotherapy for the treatment of epithelial
ovarian cancer (EOC) in combination with other eight drugs,
including the ACE inhibitor captopril. The rational is that Icatibant
would ameliorate BK-induced EOC ascites and also control the in-
creased levels of BK that result from ACE inhibition [77].
However, the multiple cross talks between the RAS and the KKS
seem to be much more complex (Fig. 4, dotted lines). There is evi-
dence that B1R expression is triggered by chronic (P7 days) ACE
inhibition in healthy subjects [12,95,106]. B2R expression was in-
creased by enalapril (ACEi) treatment in diabetic, but not healthy
mice [134]. Furthermore, it has been recognized that the beneﬁcial
effects of ACEis in cardiovascular diseases extend beyond the inhi-
bition of ACE to alter Ang II and kinin levels. It is been proposed
that ACEis enhance activity of B1R and B2R, functioning as direct
allosteric agonists of B1Rs and as indirect allosteric enhancers of
kinin activity on B2Rs via interactions with ACE, probably by for-
mation of heterodimers [34,56,82]. Endogenous peptides of the
RAS, such as Ang derivatives Ang1-7 and Ang1-9, can augment
orthosteric BK effect on B2R. In addition, it has been reported that
AT1R and B2R form constitutive heterodimers [2]. The AT1R/B2R
heterodimers display increased sensitivity toward angiotensin II
and are found in platelets and in omental vessels of preeclamptic
women [1]. However, in cultured COS-7, HEK293, and NIH3T3
cells, although both receptors were functional, no AT1R/B2R het-
erodimers were detected [71]. On the other side, AT2R overexpres-
sion in transgenic mice stimulated kallikrein activity, kinin
generation and B2R activation [169]. Other potential interactions
between the RAS and the KKS have been described and may have
important consequences in human diseases such as cancer
[153,161]. Very little is known about these potential cross talks
in the context of malignancies, particularly the existence of such
interactions in cancer cells and its consequence for the use of
RAS and KKS targeting agents for cancer treatment.
6. Conclusion
Studies with selective antagonists have provided support for
the role of kinin receptors as potential therapeutic targets in many
cancers. However, there has been limited experience with kinin
34 P.L.N. da Costa et al. / Cancer Letters 345 (2014) 27–38antagonists in clinical trials for cancer. Furthermore, in spite of
good supporting preclinical data, most kinin antagonists have
failed clinically for various conditions. This highlights the need to
reassess the drug discovery and development process for kinin
antagonists. There are various B1R and B2R antagonists available,
therefore preclinical and clinical studies utilizing the existing mol-
ecules should be considered. These molecules will likely have a
role alone or in combination with other treatment modalities.
Meanwhile, the current results also represent a potent driver force
for the discovery of new kinin receptors antagonists with improved
pharmacokinetic. Importantly, a better understanding of the rela-
tive functional roles of the B1R and B2R as well as its cross talk
with each other and with other systems/receptors, such as the
RAS and GPCRs, is likely to avoid disappointing clinical trials. It is
worth mentioning that the blockade of B2R for prolonged periods
of time may produce undesired side-effects. In contrast, the induc-
ible expression of B1R suggests that its inhibition would interfere
less with housekeeping functions, and B1R antagonists would be
attractive compounds to treat selected types of cancer.
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